Recombinant leptin (r-metHuLeptin) is a genetically engineered form of a naturally occurring cytokine hormone secreted by fat cells. Leptin appears to act primarily at the hypothalamus to regulate food intake and energy expenditure. Humans suffering from lipodystrophy, a disease characterized by loss of body fat and consequent metabolic disorders (insulin resistance, hyperglycemia, and dyslipidemia) are rendered incapable of secreting sufficient amounts of leptin due to the loss of fat. Early clinical studies have been conducted investigating leptin in the treatment of lipodystrophy.

 

This information is current as of August 29, 2005. Amgen’s product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen’s most recent Form 10-K and in Amgen’s periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.